Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): A phase III, international, randomized, placebo-controlled study
- E. Van Cutsem
- , T. Yoshino
- , H. J. Lenz
- , S. Lonardi
- , A. Falcone
- , M. L. Limón
- , M. Saunders
- , A. Sobrero
- , Y. S. Park
- , R. Ferreiro
- , Y. S. Hong
- , J. Tomasek
- , H. Taniguchi
- , F. Ciardiello
- , J. Stoehr
- , Z. Oum'hamed
- , S. Vlassak
- , M. Studeny
- , G. Argiles
- KU Leuven
- National Cancer Center Japan
- University of Southern California
- IRCCS Istituto Oncologico Veneto - Padova
- University of Pisa
- Hospital Universitario Virgen del Rocio
- The Christie NHS Foundation Trust
- University Eye Clinic
- Hospital Ramon y Cajal
- University of Ulsan
- Masaryk Memorial Cancer Institute
- Aichi Cancer Center Hospital and Research Institute
- University of Campania Luigi Vanvitelli
- Boehringer Ingelheim GmbH
- SCS Boehringer Ingelheim Comm.V
- Vall d’Hebron University Hospital
Research output: Contribution to journal › Article › peer-review
54
Link opens in a new tab
Scopus
citations